AUTHORS
Megan Bones, Jahnavi Raval, MS2, Ashley Wooten3, Ross L. Levine, Prof. Dr.4, Robert L Bowman, PhD5, Linde A Miles, PhD6
AFFILIATIONS
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
ABSTRACT
Background
Initiation of acute myeloid leukemia (AML) is driven by mutations in epigenetic modifiers, while the development and progression of AML is driven by later mutations in signaling pathways. Common epigenetic modifying mutations include IDH2 and TET2, with both having functions related to altering methylation marks blocking hematopoietic differentiation. Our single cell multiomic studies have revealed divergent immunophenotypes in NPM1-mutant AML samples harboring IDH2 or TET2 co-mutations, indicating that lineage trajectories are determined by the epigenetic mutation. Prior studies have shown that different mutations in AML drive distinct stages of clonal expansion, with epigenetic modifying mutations serving as initiating mutations and NPM1 mutations promoting late clonal expansion. Here, we report Idh2 and Tet2 mutant models to delineate the contribution of each mutation on disease progression.
Methods
We bred single (Idh2R140Q/I or Tet2-/-/T), double (Idh2R140Q or Tet2-/-+Npm1cA/IN or TN), and triple (Idh2R140Q or Tet2-/-+Npm1cA+NrasG12D/INR or TNR) mutant mice using established tamoxifen recombinase-induced mutant mouse models. For in vivo studies, isolated single, double, or triple mutant murine cells were transplanted into separate cohorts of lethally irradiated CD45.1 WT mice and subsequently treated with TAM to (in)activate mutations. Mice were regularly monitored via peripheral blood draws and flow cytometric analysis. In the ex vivo system, mutant cells were plated in co-culture with murine derived bone marrow endothelial cells (BMECs) to promote expedited cell growth, with endpoints including flow cytometry, clonal fitness assays, and bulk RNA sequencing.
Results
We first aimed to determine which co-mutations led to AML transformation. We observed that TNR and INR mutant cells both led to fulminant AML with overt leukocytosis and splenomegaly. TN and IN mutant cells were capable of transforming into lethal disease, but only after acquiring de novo mutations in the RAS/MAPK pathway, suggesting that Ras-WT cells were incapable of transformation. Flow cytometric analysis revealed an increase in the percentage of lineage negative cells in INR and TNR mice (24% v 46% IN/INR; 25% v 49% TN/TNR). We observed Ras mutations imparted a lineage switch with INR and TNR mice possessing increased immature myeloid cells compared to Ras-WT which instead possessed cells expressing mature myeloid markers. Immunophenotypic differences also emerged as a result of epigenetic mutations, with Tet2-mutant AMLs showing increased monocytic populations, in line with our AML patient data.
We next examined self-renewal capacity of mutant cells and found that Npm1 imparted significant CFU replating capacity. We further characterized LSK (Lin-Sca1+cKit+) and LK (Lin-cKit+) compartments ex vivo and demonstrated that the addition of N+R significantly increased the proportion of LK/LSKs for Tet2-mutant clones. In contrast, N+R addition in Idh2-mutant clones altered populations in a cell state specific manner. In comparing epigenetic modifiers, we found Idh2-mutant clones had significantly more LSKs compared to Tet2-mutant clones, which recapitulate our findings in AML patients.
We next analyzed the clonal fitness of Idh2 and Tet2-mutant models and found an increase in chimerism with each mutation gained, suggesting subsequent mutations progressively increase fitness. Interestingly, we observed cell state specific clonal fitness differences based on the genotype. GSEA analysis from bulk RNA-sequencing revealed elevated inflammatory pathway genes in single mutant clones that decrease with the addition of N+R mutations. We also observed decreased expression of MTOR signaling and glycolysis genes in Tet2-mutant cells, however the opposite effect is observed in Idh2-mutant cells, suggesting divergent rewiring of signaling and metabolic pathways. Additional studies have validated our RNA-sequencing results and identified novel divergent mechanisms driving Idh2- and Tet2-mutant leukemogenesis through signaling and metabolic pathway rewiring.
Conclusions
Our study shows that epigenetic mutations define divergent lineage biases and trajectories that are recapitulated in mouse models of clonal evolution. Additionally, co-mutational synergies impart genotype-specific phenotypes in Idh2 and Tet2-mutant AML. Lastly, Idh2 and Tet2-mutant clones harbor divergent metabolic requirements and signaling rewiring that drive leukemogenesis.
DISCLOSURES
Megan Bones: No relevant conflicts of interest to declare.